{
"info": {
"nct_id": "NCT00258960",
"official_title": "Phase IV/II Trial With the Combination of Pegylated Liposomal Doxorubicin (Caelyx), Cyclophosphamide and Trastuzumab in Patients With Metastatic Breast Cancer With Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2)/Neu",
"inclusion_criteria": "* Patients must sign an informed consent before of specific procedures of clinical trial.\n* Patients with histologically confirmed breast cancer and overexpression of Her2neu.\n* Age> 18 years.\n* Eastern Cooperative Oncology Group (ECOG) equal or < 2.\n* Patients have not been treated previously with chemotherapy for metastatic disease.\n* Patients must have at least one measurable lesion according to RECIST criteria.\n* Patients should have an adequate organ function to tolerate chemotherapy.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "* Patients with hypersensitivity reactions to any of the medications of the clinical trial.\n* Patients who are pregnant or lactating are not eligible.\n* Hepatic disease.\n* Not controlled active infection\n* Symptomatic metastatic brain cancer\n* Previous adjuvant treatment with anthracyclines with a total accumulated dose > 300 mg/m2 (Doxorubicin) or > 600 mg/m2 (Epirubicin)",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Patients must sign an informed consent before of specific procedures of clinical trial.",
"criterions": [
{
"exact_snippets": "Patients must sign an informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "* Patients with histologically confirmed breast cancer and overexpression of Her2neu.",
"criterions": [
{
"exact_snippets": "histologically confirmed breast cancer",
"criterion": "breast cancer",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": "histologically confirmed"
}
]
},
{
"exact_snippets": "overexpression of Her2neu",
"criterion": "Her2neu",
"requirements": [
{
"requirement_type": "expression level",
"expected_value": "overexpression"
}
]
}
]
},
{
"line": "* Age> 18 years.",
"criterions": [
{
"exact_snippets": "Age> 18 years",
"criterion": "age",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Eastern Cooperative Oncology Group (ECOG) equal or < 2.",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) equal or < 2",
"criterion": "Eastern Cooperative Oncology Group (ECOG)",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* Patients have not been treated previously with chemotherapy for metastatic disease.",
"criterions": [
{
"exact_snippets": "Patients have not been treated previously with chemotherapy for metastatic disease.",
"criterion": "previous chemotherapy treatment for metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients must have at least one measurable lesion according to RECIST criteria.",
"criterions": [
{
"exact_snippets": "at least one measurable lesion according to RECIST criteria",
"criterion": "measurable lesion",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "lesion"
}
},
{
"requirement_type": "measurement standard",
"expected_value": "RECIST criteria"
}
]
}
]
},
{
"line": "* Patients should have an adequate organ function to tolerate chemotherapy.",
"criterions": [
{
"exact_snippets": "adequate organ function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "tolerate chemotherapy",
"criterion": "chemotherapy tolerance",
"requirements": [
{
"requirement_type": "ability",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients with hypersensitivity reactions to any of the medications of the clinical trial.",
"criterions": [
{
"exact_snippets": "hypersensitivity reactions to any of the medications of the clinical trial",
"criterion": "hypersensitivity reactions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Patients who are pregnant or lactating are not eligible.",
"criterions": [
{
"exact_snippets": "Patients who are pregnant",
"criterion": "pregnancy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "lactating",
"criterion": "lactation",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Hepatic disease.",
"criterions": [
{
"exact_snippets": "Hepatic disease",
"criterion": "hepatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Not controlled active infection",
"criterions": [
{
"exact_snippets": "Not controlled active infection",
"criterion": "active infection",
"requirements": [
{
"requirement_type": "control status",
"expected_value": false
}
]
}
]
},
{
"line": "* Symptomatic metastatic brain cancer",
"criterions": [
{
"exact_snippets": "Symptomatic metastatic brain cancer",
"criterion": "metastatic brain cancer",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* Previous adjuvant treatment with anthracyclines with a total accumulated dose > 300 mg/m2 (Doxorubicin) or > 600 mg/m2 (Epirubicin)",
"criterions": [
{
"exact_snippets": "Previous adjuvant treatment with anthracyclines",
"criterion": "previous adjuvant treatment with anthracyclines",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "total accumulated dose > 300 mg/m2 (Doxorubicin)",
"criterion": "total accumulated dose of Doxorubicin",
"requirements": [
{
"requirement_type": "dose",
"expected_value": {
"operator": ">",
"value": 300,
"unit": "mg/m2"
}
}
]
},
{
"exact_snippets": "total accumulated dose > 600 mg/m2 (Epirubicin)",
"criterion": "total accumulated dose of Epirubicin",
"requirements": [
{
"requirement_type": "dose",
"expected_value": {
"operator": ">",
"value": 600,
"unit": "mg/m2"
}
}
]
}
]
}
],
"failed_miscellaneous": []
}